As filed with the Securities and Exchange Commission on May 4, 2023.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ACELYRIN, INC.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 82-2406735 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
ACELYRIN, INC.
4149 Liberty Canyon Road
Agoura Hills, California 91301
(805) 730-0360
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Shao-Lee Lin, M.D., Ph.D.
Chief Executive Officer
4149 Liberty Canyon Road
Agoura Hills, California 91301
(805) 730-0360
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Chadwick Mills Charles S. Kim Anitha Anne Cooley LLP 3 Embarcadero Center, 20th Floor San Francisco, California 94111 (415) 693-2000 |
Mardi C. Dier Chief Financial Officer and |
Alan F. Denenberg Emily Roberts Davis Polk & Wardwell LLP 1600 El Camino Real Menlo Park, California 94025 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-271244)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☐ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the Securities Act), for the sole purpose of increasing the aggregate number of shares of common stock offered by ACELYRIN, INC. (the Registrant) by 4,025,000 shares, 525,000 of which are subject to purchase upon exercise of the underwriters option to purchase additional shares of the Registrants common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-271244), including all exhibits thereto (the Earlier Registration Statement), filed by the Registrant with the Securities and Exchange Commission (the Commission) pursuant to the Securities Act, which was declared effective by the Commission on May 4, 2023, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 of the Earlier Registration Statement.
The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
EXHIBIT INDEX
* | Previously filed on the signature page to the Registrants Registration Statement on Form S-1 (File No. 333-271244), originally filed with the Securities and Exchange Commission on April 13, 2023 and incorporated by reference herein. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Agoura Hills, California on May 4, 2023.
ACELYRIN, INC. | ||
By: | /s/ Shao-Lee Lin | |
Name: | Shao-Lee Lin, M.D., Ph.D. | |
Title: | Chief Executive Officer |
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Shao-Lee Lin Shao-Lee Lin, M.D., Ph.D. |
Founder, Chief Executive Officer and Director (Principal Executive Officer) |
May 4, 2023 | ||
/s/ Mardi C. Dier Mardi C. Dier |
Chief Financial Officer and Chief Business Officer (Principal Financial and Accounting Officer) |
May 4, 2023 | ||
* Bruce C. Cozadd |
Director | May 4, 2023 | ||
* Dan Becker, M.D., Ph.D. |
Director | May 4, 2023 | ||
* Alan B. Colowick, M.D., M.P.H. |
Director | May 4, 2023 | ||
* Henry O. Gosebruch |
Director | May 4, 2023 | ||
* Patrick Machado, J.D. |
Director | May 4, 2023 | ||
* Beth Seidenberg, M.D. |
Director | May 4, 2023 | ||
* Dawn Svoronos |
Director | May 4, 2023 |
*By: | /s/ Shao-Lee Lin | |
Shao-Lee Lin, M.D., Ph.D. | ||
Attorney-in-fact |
Chadwick Mills T: (650) 843-5654 cmills@cooley.com |
Exhibit 5.1 |
May 4, 2023
ACELYRIN, INC.
4149 Liberty Canyon Road
Agoura Hills, California 91301
Ladies and Gentlemen:
We have acted as counsel to ACELYRIN, INC., a Delaware corporation (the Company), in connection with the filing by the Company of a Registration Statement on Form S-1 (the Registration Statement) with the Securities and Exchange Commission pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended, covering an underwritten public offering of up to 4,025,000 shares of the Companys common stock, par value $0.00001 per share (Shares). The Registration Statement incorporates by reference the registration statement on Form S-1 (No. 333-271244), which was declared effective on May 4, 2023 (the Prior Registration Statement), including the prospectus that is part of the Prior Registration Statement (the Prospectus).
In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the Prospectus, (b) the Companys Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws, each as currently in effect, (c) the Companys Amended and Restated Certificate of Incorporation, filed as Exhibit 3.2 to the Prior Registration Statement, and the Companys Amended and Restated Bylaws, filed as Exhibit 3.4 to the Prior Registration Statement, each of which is to be in effect in connection with the closing of the offering contemplated by the Prior Registration Statement and (d) originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below.
We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of the certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than by the Company where due authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as described in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.
Cooley LLP 3 Embarcadero Center San Francisco, CA 94111
T:+1 415 693 2000 f:+1 415 693 2222 cooley.com
May 4, 2023
Page Two
We consent to the reference to our firm under the caption Legal Matters in the Prospectus included in the Prior Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons who consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.
Sincerely,
Cooley LLP
By: | /s/ Chadwick Mills | |
Chadwick Mills |
Cooley LLP 3 Embarcadero Center San Francisco, CA 94111
T:+1 415 693 2000 f:+1 415 693 2222 cooley.com
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 24, 2023, except for the effects of the reverse stock split discussed in Note 15 to the financial statements, as to which the date is May 1, 2023, relating to the financial statements of ACELYRIN, INC., which appears in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) of ACELYRIN, INC. We also consent to the reference to us under the heading Experts in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) incorporated by reference in this Registration Statement.
/s/ PricewaterhouseCoopers LLP
San Diego, California
May 4, 2023
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 24, 2023 relating to the financial statements of ValenzaBio, Inc., which appears in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) of ACELYRIN, INC. We also consent to the reference to us under the heading Experts in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) incorporated by reference in this Registration Statement.
/s/ PricewaterhouseCoopers LLP
San Diego, California
May 4, 2023
Exhibit 23.3
Consent of Independent Auditor
We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of ACELYRIN, INC. of our report dated April 29, 2022, except for the presentation of the convertible preferred stock and common stock as described in Note 2 as to which the date is February 10, 2023, with respect to our audit of the financial statements of ValenzaBio, Inc. as of December 31, 2021, and for the year then ended.
We also consent to the reference of our firm under the caption Experts in the Registration Statement on Form S-1 (No. 333-271244) incorporated by reference in this Registration Statement.
/s/ Macias Gini & OConnell LLP
San Jose, California
May 4, 2023
Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
ACELYRIN, INC.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit(2) |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | |||||||||
Fees to Be Paid | Equity | Common stock, $0.00001 par value per share | 457(a) | 4,025,000 |
$18.00 | $72,450,000 |
0.00011020 | $7,984 | ||||||||
Total Offering Amounts | $72,450,000 |
$7,984 | ||||||||||||||
Total Fees Previously Paid | | |||||||||||||||
Total Fee Offsets | | |||||||||||||||
Net Fee Due | $7,984(3) |
(1) | Represents only the additional number of shares being registered and includes 525,000 shares of common stock issuable upon exercise of the underwriters option to purchase additional shares. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-271244), as amended (the Earlier Registration Statement). |
(2) | Based on the public offering price. |
(3) | The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities on the Earlier Registration Statement having a proposed maximum aggregate offering price of $548,550,000, which was declared effective by the Securities and Exchange Commission on May 4, 2023. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $72,450,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters option to purchase additional shares. |